Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg

Showing results (1-10 of 399) with videos related to

Pageof 40
Sort By:
MMW Fortschritte Der Medizin|March 4, 2020
[Non-alcoholic fatty liver disease (NAFLD)]Jörn M Schattenberg
Expert Opinion on Investigational Drugs|January 28, 2020
Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH)Jörn M Schattenberg
Liver International : Official Journal of the International Association for the Study of the Liver|April 26, 2019
Reading the stars for hepatic fibrosis or how to predict the severity of liver disease in patients with NASHJörn M Schattenberg
The Lancet. Gastroenterology & Hepatology|August 18, 2020
Intestinal motility: a therapeutic target for NAFLD?Jörn M Schattenberg
Gut|March 25, 2020
Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefitJörn M Schattenberg
Visceral Medicine|November 30, 2020
Emerging Pharmacological Treatment in Nonalcoholic SteatohepatitisJörn M Schattenberg
Gastroenterology & Hepatology|May 4, 2022
The Gut Microbiome and Nonalcoholic SteatohepatitisJörn M Schattenberg
Medical Network Strategy Report|July 6, 1996
Kaiser creates virtual medical group with Modesto pilot projectM Schattenberg, L Stump
Alimentary Pharmacology & Therapeutics|March 12, 2021
Editorial: the polygenic risk of cirrhosis developmentAngelo Armandi, Jörn M Schattenberg
Alimentary Pharmacology & Therapeutics|November 30, 2018
Editorial: stepwise risk stratification for both F3 and F4 in NAFLD patients-authors' replyChristian Labenz, Jörn M Schattenberg
Pageof 40

Showing results (1-10 of 399) with videos related to

Sort By:
Pageof 40
MMW Fortschritte Der Medizin|March 4, 2020
[Non-alcoholic fatty liver disease (NAFLD)]Jörn M Schattenberg
Expert Opinion on Investigational Drugs|January 28, 2020
Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH)Jörn M Schattenberg
Liver International : Official Journal of the International Association for the Study of the Liver|April 26, 2019
Reading the stars for hepatic fibrosis or how to predict the severity of liver disease in patients with NASHJörn M Schattenberg
The Lancet. Gastroenterology & Hepatology|August 18, 2020
Intestinal motility: a therapeutic target for NAFLD?Jörn M Schattenberg
Gut|March 25, 2020
Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefitJörn M Schattenberg
Visceral Medicine|November 30, 2020
Emerging Pharmacological Treatment in Nonalcoholic SteatohepatitisJörn M Schattenberg
Gastroenterology & Hepatology|May 4, 2022
The Gut Microbiome and Nonalcoholic SteatohepatitisJörn M Schattenberg
Medical Network Strategy Report|July 6, 1996
Kaiser creates virtual medical group with Modesto pilot projectM Schattenberg, L Stump
Alimentary Pharmacology & Therapeutics|March 12, 2021
Editorial: the polygenic risk of cirrhosis developmentAngelo Armandi, Jörn M Schattenberg
Alimentary Pharmacology & Therapeutics|November 30, 2018
Editorial: stepwise risk stratification for both F3 and F4 in NAFLD patients-authors' replyChristian Labenz, Jörn M Schattenberg
Pageof 40